AUCKLAND, NZ – 8 November 2018- Biomatters is proud to announce the release of Geneious Prime 2019 today with a variety of features including significantly enhanced capability for primer design, an essential part of cloning operations in commercial organizations.
New primer design functionality includes more interactive display options, simplified testing and annotation, and many useability tweaks aimed at making cloning workflows more efficient.
“Primer design has always been a crucial tool for our customers” says Head of Development Richard Moir. “We’ve focused on improving the experience of the user by taking the time to map out and understand their individual steps and the purpose behind them. Everything we’ve added has been considered from the point of a view of a biologist and aimed at creating more efficient processes ”
“As we continue to extend the core functionality of our flagship product, we get deeper involvement in the success of our biotech and pharma customers” says Matt Cawte, Chief Commercial Officer. “The latest version of Geneious Prime integrates tightly with our Geneious Biologics offering, improving organizational workflow, analytics and data integrity in the drug discovery process.”
Geneious Prime forms part of the suite of solutions created for commercial organizations, including the rapidly developing biopharma sector.
About Geneious and Biomatters
Biomatters empowers its customers with software that transforms biological data into knowledge and actionable insights across the spectrum of biotechnology research and development, including drug discovery, protein engineering and advanced comparative analysis of DNA, RNA and protein sequences. Geneious solutions are created from a deep understanding of customer experience, and turn the difficult into the intuitive and easy. That is why Geneious is trusted by over 4,000 companies, universities and institutes all over the globe.
For more information contact:
+64 21 258 1005